Dual Tissue and Liquid Biopsy Approach in ROME Trial Shows Improved Survival for Advanced Solid Tumor Patients Compared to Standard Care.

A recent clinical trial investigated a new approach to treating advanced solid tumors. The ROME phase 2 trial examined whether using both tissue and liquid biopsies to guide treatment decisions improved survival outcomes for patients with these cancers, and found that the dual-biopsy approach resulted in improved survival compared to standard treatment methods or using only a single type of biopsy. The study compared outcomes for patients receiving therapy selected based on the combined results of tissue and liquid biopsies against those receiving standard of care. The ROME trial also looked at outcomes of patients undergoing single biopsy approaches. The results indicated a notable difference in survival rates, demonstrating the potential value of integrating both biopsy types in guiding personalized cancer treatments.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Author

Mark Chiang